# A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

> **NCT00699842** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 8 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- MDS
- Low to Intermediate-1 MDS
- Non-deletion 5q

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00699842
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2011-01
- **Final completion:** 2012-05
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Administratively terminated per FDA recommendation
- **Last updated:** 2025-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00699842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00699842, "A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00699842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*